Addition of MMF to dual immunosuppression does not increase the risk of malignant short-term death after liver transplantation

J. R. Lake, K. M. David, B. J. Steffen, A. H. Chu, R. D. Gordon, R. H. Wiesner

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Immunosuppression is often incriminated for the increased risk of post-transplant malignancies. To examine whether triple- (MMF+Tacro+CS) versus dual-drug therapy (Tacro+CS) is associated with an increased incidence of malignancy, or death due to malignancy, data from a large registry of liver transplant recipients were analyzed. Data from adult primary liver recipients reported to the Scientific Registry of Transplant Recipients between June 1, 1995, and April 30, 2004, and recorded at transplant on triple-drug (n = 9180) or dual-drug (n = 10 099) therapy were included. Kaplan-Meier survival analysis showed no significant differences in death due to malignancy 4 years post-transplantation between the treatment groups. Multivariable analysis using Cox proportional hazard models confirmed no differences in risk of death due to malignancy between the groups (HR: 0.83, p = 0.107). Incidence of any post-transplant malignancy was also not significantly different. Older recipient age and cause of liver disease were significantly associated with an increased risk of malignancy-related death. These data utilizing relatively short follow-up suggest the addition of MMF to Tacro+CS at transplant is not associated with death due to malignancy, at least in the short term. Individual recipient factors appear to be important risk factors for malignancy-related death; elucidating these risk factors can assist in identifying who should be monitored most aggressively for post-transplant malignancies.

Original languageEnglish (US)
Pages (from-to)2961-2967
Number of pages7
JournalAmerican Journal of Transplantation
Volume5
Issue number12
DOIs
StatePublished - Dec 2005

Fingerprint

Liver Transplantation
Immunosuppression
Neoplasms
Transplants
Registries
Liver
Incidence
Kaplan-Meier Estimate
Survival Analysis
Proportional Hazards Models
Pharmaceutical Preparations
Liver Diseases
Transplantation
Drug Therapy
Therapeutics

Keywords

  • Immunosuppression
  • Liver transplant
  • Malignancy
  • MMF
  • Survival
  • Tacrolimus

ASJC Scopus subject areas

  • Immunology

Cite this

Addition of MMF to dual immunosuppression does not increase the risk of malignant short-term death after liver transplantation. / Lake, J. R.; David, K. M.; Steffen, B. J.; Chu, A. H.; Gordon, R. D.; Wiesner, R. H.

In: American Journal of Transplantation, Vol. 5, No. 12, 12.2005, p. 2961-2967.

Research output: Contribution to journalArticle

Lake, J. R. ; David, K. M. ; Steffen, B. J. ; Chu, A. H. ; Gordon, R. D. ; Wiesner, R. H. / Addition of MMF to dual immunosuppression does not increase the risk of malignant short-term death after liver transplantation. In: American Journal of Transplantation. 2005 ; Vol. 5, No. 12. pp. 2961-2967.
@article{c4664f0e21b248eba33711caad5206d5,
title = "Addition of MMF to dual immunosuppression does not increase the risk of malignant short-term death after liver transplantation",
abstract = "Immunosuppression is often incriminated for the increased risk of post-transplant malignancies. To examine whether triple- (MMF+Tacro+CS) versus dual-drug therapy (Tacro+CS) is associated with an increased incidence of malignancy, or death due to malignancy, data from a large registry of liver transplant recipients were analyzed. Data from adult primary liver recipients reported to the Scientific Registry of Transplant Recipients between June 1, 1995, and April 30, 2004, and recorded at transplant on triple-drug (n = 9180) or dual-drug (n = 10 099) therapy were included. Kaplan-Meier survival analysis showed no significant differences in death due to malignancy 4 years post-transplantation between the treatment groups. Multivariable analysis using Cox proportional hazard models confirmed no differences in risk of death due to malignancy between the groups (HR: 0.83, p = 0.107). Incidence of any post-transplant malignancy was also not significantly different. Older recipient age and cause of liver disease were significantly associated with an increased risk of malignancy-related death. These data utilizing relatively short follow-up suggest the addition of MMF to Tacro+CS at transplant is not associated with death due to malignancy, at least in the short term. Individual recipient factors appear to be important risk factors for malignancy-related death; elucidating these risk factors can assist in identifying who should be monitored most aggressively for post-transplant malignancies.",
keywords = "Immunosuppression, Liver transplant, Malignancy, MMF, Survival, Tacrolimus",
author = "Lake, {J. R.} and David, {K. M.} and Steffen, {B. J.} and Chu, {A. H.} and Gordon, {R. D.} and Wiesner, {R. H.}",
year = "2005",
month = "12",
doi = "10.1111/j.1600-6143.2005.01117.x",
language = "English (US)",
volume = "5",
pages = "2961--2967",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Addition of MMF to dual immunosuppression does not increase the risk of malignant short-term death after liver transplantation

AU - Lake, J. R.

AU - David, K. M.

AU - Steffen, B. J.

AU - Chu, A. H.

AU - Gordon, R. D.

AU - Wiesner, R. H.

PY - 2005/12

Y1 - 2005/12

N2 - Immunosuppression is often incriminated for the increased risk of post-transplant malignancies. To examine whether triple- (MMF+Tacro+CS) versus dual-drug therapy (Tacro+CS) is associated with an increased incidence of malignancy, or death due to malignancy, data from a large registry of liver transplant recipients were analyzed. Data from adult primary liver recipients reported to the Scientific Registry of Transplant Recipients between June 1, 1995, and April 30, 2004, and recorded at transplant on triple-drug (n = 9180) or dual-drug (n = 10 099) therapy were included. Kaplan-Meier survival analysis showed no significant differences in death due to malignancy 4 years post-transplantation between the treatment groups. Multivariable analysis using Cox proportional hazard models confirmed no differences in risk of death due to malignancy between the groups (HR: 0.83, p = 0.107). Incidence of any post-transplant malignancy was also not significantly different. Older recipient age and cause of liver disease were significantly associated with an increased risk of malignancy-related death. These data utilizing relatively short follow-up suggest the addition of MMF to Tacro+CS at transplant is not associated with death due to malignancy, at least in the short term. Individual recipient factors appear to be important risk factors for malignancy-related death; elucidating these risk factors can assist in identifying who should be monitored most aggressively for post-transplant malignancies.

AB - Immunosuppression is often incriminated for the increased risk of post-transplant malignancies. To examine whether triple- (MMF+Tacro+CS) versus dual-drug therapy (Tacro+CS) is associated with an increased incidence of malignancy, or death due to malignancy, data from a large registry of liver transplant recipients were analyzed. Data from adult primary liver recipients reported to the Scientific Registry of Transplant Recipients between June 1, 1995, and April 30, 2004, and recorded at transplant on triple-drug (n = 9180) or dual-drug (n = 10 099) therapy were included. Kaplan-Meier survival analysis showed no significant differences in death due to malignancy 4 years post-transplantation between the treatment groups. Multivariable analysis using Cox proportional hazard models confirmed no differences in risk of death due to malignancy between the groups (HR: 0.83, p = 0.107). Incidence of any post-transplant malignancy was also not significantly different. Older recipient age and cause of liver disease were significantly associated with an increased risk of malignancy-related death. These data utilizing relatively short follow-up suggest the addition of MMF to Tacro+CS at transplant is not associated with death due to malignancy, at least in the short term. Individual recipient factors appear to be important risk factors for malignancy-related death; elucidating these risk factors can assist in identifying who should be monitored most aggressively for post-transplant malignancies.

KW - Immunosuppression

KW - Liver transplant

KW - Malignancy

KW - MMF

KW - Survival

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=33644820721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644820721&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2005.01117.x

DO - 10.1111/j.1600-6143.2005.01117.x

M3 - Article

C2 - 16303011

AN - SCOPUS:33644820721

VL - 5

SP - 2961

EP - 2967

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 12

ER -